KRAS and colorectal cancer: PIK3CA (spot no. 16432), a downstream effector of RAS and mutant of PIK3CA, has been reported in in breast, ovarian, and colorectal cancer, and coexists with RAS (KRAS and NRAS) and BRAF mutations[32–35].